Abstract:Junling Li Wei Li Xiaojian Dai Dafang Zhong Yaping Ding Xiaoyan Chen 1College of Sciences, Shanghai University, Shanghai, People’s Republic of China; 2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China Background and objective: Paclitaxel protein-bound particles for injectable suspension (nab-paclitaxel) showed many advantages in safety, effectiveness, and convenience. Different from conventional formulations, the bioequivalence evaluation of nab-paclitaxel formulations requires to determine the total amount of paclitaxel in plasma and the unbound paclitaxel to reflect their in vivo disposition. This study aimed to develop an analytical method to quantify the total and unbound paclitaxel in plasma and evaluate the bioequivalence of two formulations of nab-paclitaxel in patients with breast cancer. Materials and methods: An open-label, randomized, two-period crossover study was completed among 24 Chinese patients with breast cancer. The patients were randomized to receive either the test formulation on cycle 1 day 1 and after 21 days in cycle 2 day 1 by the reference formulation (Abraxane®), or vice versa. Rapid equilibrium dialysis was adopted to separate the unbound paclitaxel in human plasma. Total and unbound paclitaxel concentrations were measured by the validated liquid chromatography–tandem mass spectrometry methods over the range of 5.00–15,000 and 0.200–200 ng/mL, respectively. The bioequivalence of the test formulation to the reference formulation was assessed using the Food and Drug Administration and European Medicines Agency guidelines. Results: All the 90% confidence intervals (CIs) of the geometric mean ratios fell within the predetermined acceptance range. The 90% CIs for the area under the concentration–time curve (AUC) from 0 h to 72 h (AUC0–t), AUC from time zero to infinity (AUC0–∞), and peak plasma concentrations (Cmax) for total paclitaxel were 92.03%–98.05%, 91.98%–99.37%, and 91.37%–99.36%, respectively. The 90% CIs of AUC0–t, AUC0–∞, and Cmax for unbound paclitaxel were 86.77%–97.88%, 86.81%–97.88%, and 87.70%–98.86%, respectively. Conclusion: Bioequivalence between the two nab-paclitaxel formulations was confirmed for total and unbound paclitaxel at the studied dose regimen.

Pharmacokinetics of F-68-modified Paclitaxel Liposomes in Rats

Quantification of paclitaxel in rat plasma by LC-MS/MS and pharmacokinetics of paclitaxel thermosensi-tive liposomes in rats

Preparation and Pharmacokinetics of Paclitaxel Nanometric Liposomes in Rats

Pharmacokinetics and Biodistribution of Polymeric Micelles of Paclitaxel with Pluronic P123

[In Vitro and in Vivo Study of Two Kinds of Long-Circulating Solid Lipid Nanoparticles Containing Paclitaxel].

Preparation and tissues distribution study of paclitaxel nanometric liposomes in mice

Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105/L101 mixed polymeric micelles.

Pharmacokinetics and biodistribution of paclitaxel-loaded pluronic P105 polymeric micelles

Pharmacokinetics and Biodistribution of Polymeric Micelles of Paclitaxel with Pluronic P105/poly(caprolactone) Copolymers.

Pharmacokinetics and Biodistribution Study of Paclitaxel Liposome in Sprague-Dawley Rats and Beagle Dogs by Liquid Chromatography-Tandem Mass Spectrometry

Tissue Distribution and Pharmacokinetics Evaluation of Domc-Fa Micelles for Intravenous Delivery of Ptx

In Vitro and in Vivo Studies on Plasma-to-blood Ratio of Paclitaxel in Human, Rabbit and Rat Blood Fractions.

Dddt_a_200679 1739..1749

Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer(64 patients) and breast cancer(62 patients)

Enhanced Oral Bioavailability of Paclitaxel in Pluronic/lhr Mixed Polymeric Micelles: Preparation, in Vitro and in Vivo Evaluation

Study on Pharmacokinetics of Taxol Injection in Rats

Pharmacokinetics and tissue distribution of paclitaxel injection based high throughput analysis

Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

An alternative paclitaxel self-emulsifying microemulsion formulation: Preparation, pharmacokinetic profile, and evaluation

Study on Cytochrome P450 Metabolic Profile of Paclitaxel on Rats using QTOF-MS